Anal Kondilom
Özet
Anal kondilom, dünya genelinde yaygın görülen, Human Papillomavirus (HPV) tip 6 ve 11 kaynaklı benign ancak bulaşıcı bir epiteliyal hastalıktır. Cinsel temasın yanı sıra vertikal veya temas yoluyla da bulaşabilen bu lezyonlar; genital, perianal ve anal bölgelerde karnabahar görünümlü kitleler olarak ortaya çıkar. Hastalık genellikle asemptomatik seyretse de kaşıntı ve kanama gibi fiziksel şikayetlerin yanı sıra anksiyete ve özgüven kaybı gibi ciddi psikoseksüel etkilere yol açabilir. Tanı aşamasında detaylı fizik muayene ve özellikle anal kanalın proktosigmoidoskopi ile değerlendirilmesi kritik öneme sahiptir. Tedavi seçenekleri arasında podofilotoksin, imiquimod ve sinecatechins gibi hastanın kendisinin uygulayabileceği topikal yöntemlerin yanı sıra kriyoterapi, trikloroasetikasit uygulaması ve cerrahi eksizyon gibi klinik müdahaleler yer almaktadır. Cerrahi yöntemler en yüksek temizlenme oranını sunarken, tüm tedavilerde %20-30 oranında rekürrens riski mevcuttur. Ciddi toksik etkileri nedeniyle podofilin kullanımı kesinlikle önerilmemektedir. Erken teşhis ve multidisipliner yaklaşım, hem lezyonların temizlenmesi hem de olası malign transformasyonların önlenmesi açısından hayatidir.
Anal condyloma is a common, infectious benign epithelial disease caused by Human Papillomavirus (HPV) types 6 and 11, observed worldwide. These lesions, which can be transmitted through sexual contact as well as vertical or direct contact, manifest as cauliflower-like masses in the genital, perianal, and anal regions. Although the disease is generally asymptomatic, it can lead to physical complaints such as itching and bleeding, as well as significant psychosexual effects like anxiety and loss of self-esteem. In the diagnosis stage, a detailed physical examination and especially the evaluation of the anal canal via proctosigmoidoscopy are of critical importance. Treatment options include patient-applied topical methods such as podophyllotoxin, imiquimod, and sinecatechins, alongside clinical interventions like cryotherapy, trichloroacetic acid application, and surgical excision. While surgical methods offer the highest clearance rates, there is a 20-30% risk of recurrence across all treatments. The use of podophyllin is strictly discouraged due to severe toxic effects. Early diagnosis and a multidisciplinary approach are vital for both the clearance of lesions and the prevention of potential malignant transformations.
Referanslar
Alam M, Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol. 2001;137(3):337-41.
Rozmus-Warcholińska W, Loch T, et al. [Genital warts associated with HPV infection during II and III trimester of pregnancy--a case report and analysis of treatment options]. Ginekol Pol. 2007;78(11):888-91.
Sultan S. [Anal condyloma: its management is still difficult]. J Chir (Paris). 2001;138(5):277-80.
De Panfilis G, Melzani G, Mori G, et al. Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis. 2002;29(3):121-5.
Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol. 1999;37(10):3316-22.
Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J. 2006;12(3):5.
Roongpisuthipong A, Chalermchockcharoenkit A, Thamkhantho M, et al. Current therapy for condyloma acuminata of the patients attending female STD Unit, Siriraj Hospital. J Med Assoc Thai. 2010;93(6):643-6.
Sherrard J, Riddell L. Comparison of the effectiveness of commonly used clinic-based treatments for external genital warts. Int J STD AIDS. 2007;18(6):365-8.
Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731-8.
Arima Y, Winer RL, Feng Q, et al. Development of genital warts after incident detection of human papillomavirus infection in young men. J Infect Dis. 2010;202(8):1181-4.
Jin F, Prestage GP, Kippax SC, et al. Risk factors for genital and anal warts in a prospective cohort of HIV-negative homosexual men: the HIM study. Sex Transm Dis. 2007;34(7):488-93.
Sonnex C, Scholefield JH, Kocjan G, et al. Anal human papillomavirus infection in heterosexuals with genital warts: prevalence and relation with sexual behaviour. Bmj. 1991;303(6812):1243.
Drolet M, Brisson M, Maunsell E, et al. The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis. 2011;38(10):949-56.
Sénécal M, Brisson M, Maunsell E, et al. Loss of quality of life associated with genital warts: baseline analyses from a prospective study. Sex Transm Infect. 2011;87(3):209-15.
Dominiak-Felden G, Cohet C, Atrux-Tallau S, et al. Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK. BMC Public Health. 2013;13:1065.
Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS. 1998;9(10):571-8.
Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect. 2008;84(3):161-6.
Schlecht HP, Fugelso DK, Murphy RK, et al. Frequency of occult high-grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men. Clin Infect Dis. 2010;51(1):107-10.
Kreuter A, Siorokos C, Oellig F, et al. High-grade Dysplasia in Anogenital Warts of HIV-Positive Men. JAMA Dermatol. 2016;152(11):1225-30.
Ikenberg H, Gissmann L, Gross G, et al. Human papillomavirus type-16-related DNA in genital Bowen's disease and in Bowenoid papulosis. Int J Cancer. 1983;32(5):563-5.
Gilson R, Nugent D, Werner RN, et al. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 2020;34(8):1644-53.
Kumar B, Gupta S. The acetowhite test in genital human papillomavirus infection in men: what does it add? J Eur Acad Dermatol Venereol. 2001;15(1):27-9.
Kirby P, Dunne A, King DH, et al. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med. 1990;88(5):465-9.
Claesson U, Lassus A, Happonen H, et al. Topical treatment of venereal warts: a comparative open study of podophyllotoxin cream versus solution. Int J STD AIDS. 1996;7(6):429-34.
Edwards A, Atma-Ram A, Thin RN. Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts. Genitourin Med. 1988;64(4):263-5.
Beutner KR, Conant MA, Friedman-Kien AE, et al. Patient-applied podofilox for treatment of genital warts. Lancet. 1989;1(8642):831-4.
von Krogh G, Szpak E, Andersson M, et al. Self-treatment using 0.25%-0.50% podophyllotoxin-ethanol solutions against penile condylomata acuminata: a placebo-controlled comparative study. Genitourin Med. 1994;70(2):105-9.
Strand A, Brinkeborn RM, Siboulet A. Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution. Genitourin Med. 1995;71(6):387-90.
Lacey CJ, Goodall RL, Tennvall GR, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect. 2003;79(4):270-5.
Murray ML, Meadows J, Doré CJ, et al. Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial). BMC Med Res Methodol. 2018;18(1):125.
Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998;38(2 Pt 1):230-9.
Beutner KR, Tyring SK, Trofatter KF, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother. 1998;42(4):789-94.
Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol. 1998;134(1):25-30.
Fife KH, Ferenczy A, Douglas JM, et al. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. Sex Transm Dis. 2001;28(4):226-31.
Arican O, Guneri F, Bilgic K, et al. Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol. 2004;31(8):627-31.
Garland SM, Waddell R, Mindel A, et al. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int J STD AIDS. 2006;17(7):448-52.
Ciavattini A, Tsiroglou D, Vichi M, et al. Topical Imiquimod 5% cream therapy for external anogenital warts in pregnant women: report of four cases and review of the literature. J Matern Fetal Neonatal Med. 2012;25(7):873-6.
Lin JK, Liang YC. Cancer chemoprevention by tea polyphenols. Proc Natl Sci Counc Repub China B. 2000;24(1):1-13.
Tatti S, Swinehart JM, Thielert C, et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol. 2008;111(6):1371-9.
Tzellos TG, Sardeli C, Lallas A, et al Efficacy, safety and tolerability of green tea catechins in the treatment of external anogenital warts: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2011;25(3):345-53.
Godley MJ, Bradbeer CS, Gellan M, et al. Cryotherapy compared with trichloroacetic acid in treating genital warts. Genitourin Med. 1987;63(6):390-2.
Stone KM, Becker TM, Hadgu A, et al. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin Med. 1990;66(1):16-9.
Handley JM, Maw RD, Horner T, et al. Non-specific immunity in patients with primary anogenital warts treated with interferon alpha plus cryotherapy or cryotherapy alone. Acta Derm Venereol. 1992;72(1):39-40.
Stefanaki C, Katzouranis I, Lagogianni E, et al. Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts. Int J STD AIDS. 2008;19(7):441-4.
Gilson RJ, Ross J, Maw R, et al. A multicentre, randomised, double-blind, placebo controlled study of cryotherapy versus cryotherapy and podophyllotoxin cream as treatment for external anogenital warts. Sex Transm Infect. 2009;85(7):514-9.
Azizjalali M, Ghaffarpour G, Mousavifard B. CO(2) Laser therapy versus cryotherapy in treatment of genital warts; a Randomized Controlled Trial (RCT). Iran J Microbiol. 2012;4(4):187-90.
Camargo CL, Belda Junior W, Fagundes LJ, et al. A prospective, open, comparative study of 5% potassium hydroxide solution versus cryotherapy in the treatment of genital warts in men. An Bras Dermatol. 2014;89(2):236-40.
Mistrangelo M. Surgical treatment of anal condylomata acuminata. Dis Colon Rectum. 2009;52(10):1803; author reply
Mi X, Chai W, Zheng H, Zuo YG, et al. A randomized clinical comparative study of cryotherapy plus photodynamic therapy vs. cryotherapy in the treatment of multiple condylomata acuminata. Photodermatol Photoimmunol Photomed. 2011;27(4):176-80.
Lin MC, Cheng HW, Tsai YC, et al. Podophyllin, but not the constituents quercetin or kaempferol, induced genotoxicity in vitro and in vivo through ROS production. Drug Chem Toxicol. 2009;32(1):68-76.
